Gen-Plus
Gen-Plus is a Munich-based pharmaceutical CDMO providing formulation development and GMP manufacturing of complex drug products (solids, semi-solids, transdermal patches, oral films) for big pharma, generics, biotech, and compounding pharmacy clients across Europe, the Americas, Australia, and Israel.
- Company typePrivate
- Founded1999
- HeadquartersMunich, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Gen-Plus does
Gen-Plus GmbH & Co. KG is a Munich-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 1999, specializing in formulation development and GMP-certified manufacturing of complex and hard-to-formulate drug products. The company operates a 1000 sqm GMP facility and serves pharmaceutical clients across solid dosage forms (tablets, capsules, granules, pellets, lyophilisates), semi-solid formulations, transdermal patches, oral thin films, and micro/nanoemulsions. Its technology platform spans 30+ pharmaceutical technologies including hot melt extrusion for bioavailability enhancement, 2D/3D drug printing for personalized medicine, high containment capabilities for highly potent and cytotoxic APIs (OEB classes 4/5), multiple amorphization methods, and PLEASE laser perforation technology for transdermal peptide delivery.
The company generates revenue through project-based contract R&D services, feasibility studies, proof-of-concept work, GMP manufacturing of Phase I clinical trial samples (with IMP manufacturing capabilities for oral solids and extension to ODFs/TDS), patent support and freedom-to-operate consulting, and analytical services including in-vitro permeation testing. Its customer base is horizontally diversified across big pharma, generic manufacturers, biotech startups, OTC/dietary supplement companies, and compounding pharmacies, with project footprints in Europe, the USA, Australia, Israel, and Latin America. Gen-Plus is a privately held company that has operated as a subsidiary of Conscio Group since August 2022, following an earlier 2015 management buy-out from Teva/Ratiopharm by Dr. Markus Dachtler. Leadership transitioned in October 2023, with Tanja Führmann appointed CEO and Managing Director.
Gen-Plus firmographics
Firmographics- Name
- Gen-Plus
- Legal name
- Gen-Plus GmbH & Co. KG
- Website
- https://gen-plus.de
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gen-Plus is a Munich-based pharmaceutical CDMO providing formulation development and GMP manufacturing of complex drug products (solids, semi-solids, transdermal patches, oral films) for big pharma, generics, biotech, and compounding pharmacy clients across Europe, the Americas, Australia, and Israel.
- Ownership category
- akta.pro rank
Gen-Plus industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule API & Intermediates CDMO (HLAGABAA)
Keywords
Where Gen-Plus is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Gen-Plus business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Contract R&D Services: Gen-Plus provides formulation development, feasibility studies, and proof-of-concept services for pharmaceutical companies. Revenue generated through project-based contract work from early idea phase through clinical trial sample production.
- GMP Manufacturing: Certified manufacturer for Phase I clinical trial samples and IMP production. Revenue from GMP-compliant manufacturing of oral solids, with extension to oral films (ODFs) and transdermal therapeutic systems (TDS) under preparation.
- Patent and Consulting Services: Patent support including freedom-to-operate strategies and general pharmaceutical consulting services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based contract services |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Gen-Plus product offering
Product offeringCore offering
Gen-Plus is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing formulation development and GMP manufacturing services for solid, semi-solid, transdermal, and personalized dosage forms. The company offers end-to-end services from early-stage feasibility studies through Phase I clinical trial sample production, specializing in complex and hard-to-formulate APIs, high-potency substances, narcotics, and 2D/3D printed personalized medicines across its 1,000 sqm GMP facility in Munich.
Product overview
Gen-Plus is a versatile Contract Development and Manufacturing Organization (CDMO) offering pharmaceutical innovation services from idea to production. The company operates as part of the Conscio Group and provides a comprehensive portfolio organized into three main categories: (1) Development Services including Original Products/NCE/NDA formulation, Generika/OTC, Biotech/Analytic, Feasibility Studies, Patent Support, Analytic Services, Narcotics Handling, and Consulting/Compliance; (2) Manufacturing Services for Investigational Medicinal Products (IMP) for clinical trials; and (3) Technology Platforms including 2D/3D Printing for personalized medication, Solid Dosage Forms, Semi-solid Dosage Forms, Patches/Oral Thin Films, Hot Melt Extrusion (HME), Micro-/Nanoemulsions, API Amorphization, High Containment Technologies, and PLEASE Laser Technology. The 1,000 sqm GMP facility enables the company to serve pharmaceutical clients from early development through clinical sample production and scale-up.
Differentiator
Problem solved
Functional benefit
Products and services
- Original Products / NCE / NDA Formulation Development
- Generics / OTC Product Development
- Biotech Formulation Development
- Feasibility Studies and Proof of Concept
- Investigational Medicinal Product (IMP) Manufacturing
- Patent Support Services
- Analytic Services
- Narcotics Handling Services
- Pharmaceutical Consulting and Compliance
- 2D/3D Drug Printing Technology Service
Quantifiable outcome
- Successfully developed over 60 drug products using high-potent APIs
- +1 more outcomes
Companies that use Gen-Plus
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles4 records
Gen-Plus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Gen-Plus partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Conscio GroupcoreGen-Plus entered into a strategic partnership with Conscio Group, an independent international network of scientific service providers. The partnership enables an end-to-end service offering from idea to commercialization, combining Gen-Plus formulation and GMP production with Conscio's clinical trials, bioanalytical testing, and pharmaceutical testing capabilities.
- PCCA (Professional Compounding Centers of America)coreLong-term collaboration with Houston-based PCCA, a leading supplier of APIs, excipients and drug delivery technology to compounding pharmacies. Gen-Plus provides formulation development, technical assistance, and GMP mindset compliance for personalized medication formulations. The collaboration includes stability testing and physicochemical characterization of compounded formulations.
- TH Köln (Technical University of Cologne)minorResearch collaboration in the PolyPrint project developing new 3D printers and polymers for pharmaceutical printing. TH Köln focuses on developing multi-head 3D printer systems for combining several active ingredients.
- Heinrich Heine University Düsseldorf (HHU)minorResearch partner in PolyPrint consortium developing pharmaceutical 3D printing. HHU team works on filament production processes and printing of first tablets using new polymers.
- MerckminorPartner in PolyPrint research project developing pharmaceutical 3D printing. Merck's Life Science business sector developed new polymers enabling improved properties for extrusion, compression and stabilization of drug substances.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
Gen-Plus competitors and assessment
Company assessmentDirect peers
- Hermes Arzneimittel: German specialty pharmaceutical manufacturer and CDMO with capabilities in solid dosage forms, OTC, and niche formulations. Comparable in geography, dosage-form focus, and serving German and European pharma clients.
- Quotient Sciences: UK-based CDMO specializing in early-phase drug development and clinical trial manufacturing, with a strong focus on integrated formulation-to-clinic services. Directly comparable to Gen-Plus' early-phase, formulation-led CDMO positioning.
- Recipharm: European CDMO with extensive solid dose, semi-solid, and complex formulation capabilities serving big pharma and generics. Highly comparable in customer mix (big pharma + generic manufacturers) and dosage-form focus, though at much larger scale.
- Aprecia Pharmaceuticals: US-based pharmaceutical company pioneering 3D-printed drugs (Spritam). Most direct comparable to Gen-Plus' 2D/3D printing competence center for personalized, small-batch, point-of-care manufacturing.
- Aenova Group: One of the largest CDMOs in Europe, headquartered in Germany, with broad solid and semi-solid dosage form development and manufacturing capabilities. Comparable to Gen-Plus in focus on oral solids and complex formulations, but at materially greater scale.
- CoreRx: US-based small-molecule CDMO focused on complex oral solids, pre-formulation, and GMP clinical manufacturing. Comparable in targeting early-phase, complex-formulation clients with project-based service model.
Broad incumbents
- Patheon (Thermo Fisher Scientific): Global CDMO (part of Thermo Fisher) offering comprehensive drug substance and drug product services including oral solids, semi-solids, and complex formulations. Broad incumbent competitor to Gen-Plus' formulation/GMP services.
- Catalent: Global CDMO leader with deep capabilities in oral solid dose, softgel, and novel drug delivery. Overlaps with Gen-Plus' solid/semi-solid and transdermal expertise but operates at vastly greater scale and modality breadth.
- PCI Pharma Services: Global CDMO providing clinical and commercial supply, manufacturing, and packaging for oral solid dose and specialty formulations. Overlaps with Gen-Plus' clinical trial material manufacturing focus at much broader geographic and scale footprint.
Emerging players
- Laxxon Medical: Emerging 3D pharmaceutical printing company developing oral dosage forms with tailored release profiles. Comparable to Gen-Plus' 2D/3D printing and personalized medicine focus, though at an earlier commercialization stage.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Gen-Plus social profiles
Digital presenceGen-Plus compliance and trust
Trust signalCompliance5 records
Gen-Plus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gen-Plus leadership team
Management profileNumber of profiles
Profiles2 records
Gen-Plus funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gen-Plus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gen-Plus
What does Gen-Plus do?
Gen-Plus is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing formulation development and GMP manufacturing services for solid, semi-solid, transdermal, and personalized dosage forms. The company offers end-to-end services from early-stage feasibility studies through Phase I clinical trial sample production, specializing in complex and hard-to-formulate APIs, high-potency substances, narcotics, and 2D/3D printed personalized medicines across its 1,000 sqm GMP facility in Munich.
Is Gen-Plus a public or private company?
Gen-Plus is a private company. It is classified as corporate owned and is currently operating.
When was Gen-Plus founded?
Gen-Plus was founded in 1999. It employs 11 to 50 people.
Where is Gen-Plus based?
Gen-Plus is headquartered in Munich, Germany, in the Europe region.
How does Gen-Plus make money?
Three revenue lines are on record. Contract R&D Services are the primary driver. The others are GMP Manufacturing and patent and Consulting Services.
Who are Gen-Plus's main competitors?
Direct peers on record are Hermes Arzneimittel, Quotient Sciences, Recipharm, Aprecia Pharmaceuticals, Aenova Group and CoreRx. Broad incumbents are Patheon (Thermo Fisher Scientific), Catalent and PCI Pharma Services. Laxxon Medical is listed as an emerging player.
Does Gen-Plus have an API?
No public API is recorded for Gen-Plus.
What industry is Gen-Plus in?
Gen-Plus's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.